The Food and Drug Administration (FDA) maintains a useful resource for clinicians that describes substrates, inhibitors, and inducers of CYP enzymes.14 When evaluating DDIs in acutely ill patients with COVID-19, the extent of the change in exposure (ie, the change in the AUC of the victim drug) and the time course of this change are important considerations. This evidence concerns the gene PPIG and COVID-19.